Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma.

ABSTRACT: Head and neck cancer affects nearly 750,000 patients, with more than 300,000 deaths annually. Advances in first line surgical treatment have improved survival rates marginally particularly in developed countries, however survival rates for aggressive locally advanced head and neck cancer are still poor. Recurrent and metastatic disease remains a significant problem for patients and the health system. As our knowledge of the genomic landscape of the head and neck cancers continues to expand, there are promising developments occurring in molecular therapies available for advanced or recalcitrant disease. The concept of precision medicine is underpinned by our ability to accurately sequence tumour samples to best understand individual patient genomic variations and to tailor targeted therapy

SUBMITTER: Kordbacheh F 

PROVIDER: S-EPMC8582411 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature